{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:31:09Z","timestamp":1776382269411,"version":"3.51.2"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,6]],"date-time":"2011-05-06T00:00:00Z","timestamp":1304640000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s11060-011-0602-9","type":"journal-article","created":{"date-parts":[[2011,5,5]],"date-time":"2011-05-05T08:50:17Z","timestamp":1304585417000},"page":"375-381","source":"Crossref","is-referenced-by-count":21,"title":["Phase I and pharmacokinetic study of COL-3 in patients with recurrent high-grade gliomas"],"prefix":"10.1007","volume":"105","author":[{"given":"Michelle A.","family":"Rudek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"New","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Surasak","family":"Phuphanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane B.","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis B.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Piantadosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart A.","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,6]]},"reference":[{"key":"602_CR1","first-page":"237","volume":"11","author":"SA Grossman","year":"1997","unstructured":"Grossman SA, Levin V, Sawaya R, Maor M, Loeffler J (1997) National comprehensive cancer network adult brain tumor practice guidelines. Oncology 11:237\u2013277","journal-title":"Oncology"},{"key":"602_CR2","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"602_CR3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.1994.tb24782.x","volume":"732","author":"PC Costello","year":"1994","unstructured":"Costello PC, Del Maestro RF, Stetler-Stevenson WG (1994) Gelatinase A expression in human malignant gliomas. Ann N Y Acad Sci 732:450\u2013452","journal-title":"Ann N Y Acad Sci"},{"key":"602_CR4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/(SICI)1097-0142(19980301)82:5<923::AID-CNCR18>3.0.CO;2-2","volume":"82","author":"MH Friedberg","year":"1998","unstructured":"Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G (1998) Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer 82:923\u2013930","journal-title":"Cancer"},{"key":"602_CR5","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1023\/A:1006760632766","volume":"17","author":"Z Kachra","year":"1999","unstructured":"Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, Del Maestro R, Beliveau R (1999) Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 17:555\u2013566","journal-title":"Clin Exp Metastasis"},{"key":"602_CR6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00157684","volume":"14","author":"RE Sawaya","year":"1996","unstructured":"Sawaya RE, Yamamoto M, Gokaslan ZL, Wang SW, Mohanam S, Fuller GN, McCutcheon IE, Stetler-Stevenson WG, Nicolson GL, Rao JS (1996) Expression and localization of 72\u00a0kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clin Exp Metastasis 14:35\u201342","journal-title":"Clin Exp Metastasis"},{"key":"602_CR7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02483449","volume":"20","author":"M Wang","year":"2003","unstructured":"Wang M, Wang T, Liu S, Yoshida D, Teramoto A (2003) The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathol 20:65\u201372","journal-title":"Brain Tumor Pathol"},{"key":"602_CR8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/labinvest.3700003","volume":"84","author":"KV Lu","year":"2004","unstructured":"Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS (2004) Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 84:8\u201320","journal-title":"Lab Invest"},{"key":"602_CR9","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/(SICI)1097-0215(19990301)80:5<764::AID-IJC22>3.0.CO;2-J","volume":"80","author":"JC Tonn","year":"1999","unstructured":"Tonn JC, Kerkau S, Hanke A, Bouterfa H, Mueller JG, Wagner S, Vince GH, Roosen K (1999) Effect of synthetic matrix-metalloproteinase inhibitors on invasive capacity and proliferation of human malignant gliomas in vitro. Int J Cancer 80:764\u2013772","journal-title":"Int J Cancer"},{"key":"602_CR10","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1186\/1471-2407-10-339","volume":"10","author":"H Nakabayashi","year":"2010","unstructured":"Nakabayashi H, Yawata T, Shimizu K (2010) Anti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cells. BMC Cancer 10:339","journal-title":"BMC Cancer"},{"key":"602_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/10454411910020030201","volume":"2","author":"LM Golub","year":"1991","unstructured":"Golub LM, Ramamurthy NS, McNamara TF, Greenwald RA, Rifkin BR (1991) Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. Crit Rev Oral Biol Med 2:297\u2013321","journal-title":"Crit Rev Oral Biol Med"},{"key":"602_CR12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/jnci\/93.3.178","volume":"93","author":"M Hidalgo","year":"2001","unstructured":"Hidalgo M, Eckhardt SG (2001) Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 93:178\u2013193","journal-title":"J Natl Cancer Inst"},{"key":"602_CR13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1200\/JCO.2001.19.2.584","volume":"19","author":"MA Rudek","year":"2001","unstructured":"Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E (2001) Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J Clin Oncol 19:584\u2013592","journal-title":"J Clin Oncol"},{"key":"602_CR14","doi-asserted-by":"crossref","first-page":"6512","DOI":"10.1158\/1078-0432.CCR-04-0804","volume":"10","author":"S Syed","year":"2004","unstructured":"Syed S, Takimoto C, Hidalgo M, Rizzo J, Kuhn JG, Hammond LA, Schwartz G, Tolcher A, Patnaik A, Eckhardt SG, Rowinsky EK (2004) A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res 10:6512\u20136521","journal-title":"Clin Cancer Res"},{"key":"602_CR15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1200\/JCO.20.1.153","volume":"20","author":"M Cianfrocca","year":"2002","unstructured":"Cianfrocca M, Cooley TP, Lee JY, Rudek MA, Scadden DT, Ratner L, Pluda JM, Figg WD, Krown SE, Dezube BJ (2002) Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi\u2019s sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 20:153\u2013159","journal-title":"J Clin Oncol"},{"key":"602_CR16","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10637-006-9031-6","volume":"25","author":"QS Chu","year":"2007","unstructured":"Chu QS, Forouzesh B, Syed S, Mita M, Schwartz G, Cooper J, Curtright J, Rowinsky EK (2007) A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas. Invest New Drugs 25:359\u2013367","journal-title":"Invest New Drugs"},{"key":"602_CR17","first-page":"471","volume":"137","author":"JV Ghate","year":"2001","unstructured":"Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E (2001) Drug-induced lupus associated with COL-3: report of 3 cases. Arch Dermatol 137:471\u2013474","journal-title":"Arch Dermatol"},{"key":"602_CR18","first-page":"2940","volume":"9","author":"MR Gilbert","year":"2003","unstructured":"Gilbert MR, Supko JG, Batchelor T, Lesser G, Fisher JD, Piantadosi S, Grossman S (2003) Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9:2940\u20132949","journal-title":"Clin Cancer Res"},{"key":"602_CR19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jpba.2004.10.052","volume":"37","author":"MA Rudek","year":"2005","unstructured":"Rudek MA, Hartke C, Zabelina Y, Zhao M, New P, Baker SD (2005) A sensitive method for determination of COL-3, a chemically modified tetracycline, in human plasma using high-performance liquid chromatography and ultraviolet detection. J Pharm Biomed Anal 37:751\u2013756","journal-title":"J Pharm Biomed Anal"},{"key":"602_CR20","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1177\/0091270003256675","volume":"43","author":"MA Rudek","year":"2003","unstructured":"Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD (2003) Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies. J Clin Pharmacol 43:1124\u20131135","journal-title":"J Clin Pharmacol"},{"key":"602_CR21","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11095-004-1877-8","volume":"22","author":"J Li","year":"2005","unstructured":"Li J, Zhou S, Huynh H, Chan E (2005) Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharm Res 22:397\u2013404","journal-title":"Pharm Res"},{"key":"602_CR22","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1023\/A:1020901328583","volume":"19","author":"J Li","year":"2002","unstructured":"Li J, Huynh H, Chan E (2002) Evidence for dissolution rate-limited absorption of COL-3, a Matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration. Pharm Res 19:1655\u20131662","journal-title":"Pharm Res"},{"key":"602_CR23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1345\/aph.17332","volume":"32","author":"GD Anderson","year":"1998","unstructured":"Anderson GD (1998) A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 32:554\u2013563","journal-title":"Ann Pharmacother"},{"key":"602_CR24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-2952(93)90064-4","volume":"45","author":"L Sutherland","year":"1993","unstructured":"Sutherland L, Ebner T, Burchell B (1993) The expression of UDP-glucuronosyltransferases of the UGT1 family in human liver and kidney and in response to drugs. Biochem Pharmacol 45:295\u2013301","journal-title":"Biochem Pharmacol"},{"key":"602_CR25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s11060-006-9160-y","volume":"80","author":"MD Groves","year":"2006","unstructured":"Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA (2006) Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. J Neurooncol 80:83\u201390","journal-title":"J Neurooncol"},{"key":"602_CR26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.20.5.1383","volume":"20","author":"MD Groves","year":"2002","unstructured":"Groves MD, Puduvalli VK, Hess KR, Jaeckle KA, Peterson P, Yung WK, Levin VA (2002) Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 20:1383\u20131388","journal-title":"J Clin Oncol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0602-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-011-0602-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-011-0602-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T14:23:41Z","timestamp":1560176621000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-011-0602-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,6]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["602"],"URL":"https:\/\/doi.org\/10.1007\/s11060-011-0602-9","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,6]]}}}